Emma Otieno is a New York, New York based female podiatrist who is specialized in Podiatry. Active license number of Emma Otieno for Podiatry is N007235 in New York. Emma Otieno is qualified with a Doctor of Podiatric Medicine (D.P.M.) degree, licensed by the state, and practicing within the scope of that license. She diagnose and treat foot diseases and deformities. She can perform medical, surgical and other operative procedures, prescribe corrective devices and prescribe and administer drugs and physical therapy.
Complete Profile:
Emma Otieno speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Podiatrist
Credentials:
DPM
Gender:
Female
Practice Address:
208 E 116th St, New York, New York, 10029-1451
Phone:
646-441-0294
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1730716119
NPI Enumeration Date:
25 Mar, 2020
NPI Last Update On:
26 Sep, 2024
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Emma Otieno are as mentioned below.
License Number
Specialization
State
Status
N007235
Podiatry
New York
Primary
01157
Podiatry
Connecticut
Secondary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
208 E 116th St Frnt A, New York, New York
Zip:
10029-1451
Phone Number:
646-441-0294
Fax Number:
--
Patients can reach Emma Otieno at 208 E 116th St, New York, New York or can call to book an appointment on 646-441-0294. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 14 October, 2024.